Abstract: Objective To investigate the relationship between glutathione S-transferase P1（GSTP1） and ATP-binding cassette sub-family C member 2（ABCC2） genetic polymorphisms and the sensitivity of platinum-based chemotherapy in advanced non-small cell lung cancer（NSCLC） patients of Xinjiang Uygur. Methods Genetic DNA were extracted from the venous of a total of 112 Uygur patients with advanced NSCLC who received platinum-based chemotherapy. Among the 112 patients， there were 32 cases of paclitaxel+cisplatin regimen， 29 cases of gemcitabine+cisplatin regimen， and 51 cases of pemetrexed+cisplatin regimen. The clinical response was evaluated after two cycles of chemotherapy. GSTP1 rs1695 and ABCC2 rs717620， rs2273697， rs3740066 were genotyped using PCR-restriction fragment length polymorphism method， and the relationship between GSTP1， ABCC2 polymorphisms and chemotherapy sensitivity was analyzed. Results The genotype frequencies of GSTP1 rs1695 and ABCC2 rs717620， rs2273697， rs3740066A were accorded with Hardy-Weinberg equilibrium（P>0.05）. After two cycles’ chemotherapy， there were 32 cases of PR， 61 cases of SD， and 19 cases of PD，and the sensitivity was 28.6%. Age， gender， pathological type， stage， ECOG score and chemotherapy were not related to sensitivity（P>0.05）. The GSTP1 rs1695 and ABCC2 rs717620 genetic polymorphisms， but not ABCC2 rs2273697 and rs3740066 were found to be related to the sensitivity（P>0.05）. Patients with GSTP1 rs1695 AA and ABCC2 rs717620 CT+TT genotypes showed the sensitivity of 50.0% compared to 16.7% of GSTP1 rs1695 AA and ABCC2 rs717620 CC（P<0.05）. Conclusion The GSTP1 rs1695 and ABCC2 rs717620 polymorphisms might be potential prognostic factors of clinical response in advanced NSCLC patients of Xinjiang Uygur receiving platinum-based chemotherapy.